Anzeige
Mehr »
Dienstag, 09.09.2025 - Börsentäglich über 12.000 News
Tokenisierung entfesselt: Republic führt die Ethereum-Revolution
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QNWR | ISIN: US8808811074 | Ticker-Symbol: 430
Tradegate
05.09.25 | 21:10
6,150 Euro
-0,81 % -0,050
1-Jahres-Chart
TERNS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
TERNS PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
6,1506,25008.09.
6,1506,25008.09.

Aktuelle News zur TERNS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.08.Terns Pharmaceuticals stock rating reiterated at Mizuho amid oral GLP-1 market shifts6
06.08.Terns to stop funding metabolic disease trials beyond 2025, seeks partners for assets20
TERNS PHARMACEUTICALS Aktie jetzt für 0€ handeln
06.08.Terns Pharmaceuticals, Inc. Loss At -$24.09 Mln In Q24
05.08.Terns Pharmaceuticals GAAP EPS of -$0.26 beats by $0.034
05.08.Terns Pharmaceuticals, Inc. - 10-Q, Quarterly Report1
05.08.Terns Pharmaceuticals, Inc. - 8-K, Current Report1
23.06.Terns completes enrollment in Phase 2 obesity drug trial7
23.06.Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions196Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study; topline data were presented in September 2024 Phase 2 FALCON clinical trial of TERN-601 completed enrollment...
► Artikel lesen
17.06.Citizens JMP reiterates Terns Pharmaceuticals stock rating on positive data2
16.06.Terns Pharmaceuticals, Inc. - 8-K, Current Report1
14.05.Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-7015
13.05.BMO Capital cuts Terns Pharma stock target to $15, keeps Outperform16
09.05.Terns Pharmaceuticals GAAP EPS of -$0.262
02.05.Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)219FOSTER CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule...
► Artikel lesen
21.04.JMP maintains $20 target on Terns stock amid GLP-1RA developments6
15.04.Mizuho maintains Outperform on Terns Pharma, $14 target5
02.04.Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)181FOSTER CITY, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
► Artikel lesen
20.03.Terns Pharmaceuticals GAAP EPS of -$0.24 beats by $0.073
20.03.Terns Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
20.03.Terns Pharmaceuticals, Inc. - 10-K, Annual Report1
Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1